-
-
-
-
-
-
-
Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease
64,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

